C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 471/04 (2006.01) A61K 31/4375 (2006.01) A61K 31/663 (2006.01)
Patent
CA 2277273
This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. The vitronectin receptor antagonist compounds of the present invention are .alpha.v.beta.3 antagonists, .alpha.v.beta.5 antagonists or dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.
L'invention concerne certains nouveaux composés et leurs derivés, leur synthèse et leur utilisation comme antagonistes de récepteur vitronectine. Les composés antagonistes de récepteur de vitronectine décrits sont des antagonistes alpha v beta 3, des antagonistes alpha v beta 5 ou des antagonistes doubles alpha v beta 3/ alpha v beta 5, utiles pour inhiber la résorption osseuse, traiter et prévenir l'ostéoporose et inhiber la resténose, la rétinopathie diabétique, la dégénérescence maculaire, l'angiogénèse, l'athérosclérose, l'inflammation, les maladies virales et la croissance tumorale.
Merck & Co. Inc.
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
LandOfFree
Integrin antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Integrin antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Integrin antagonists will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1738253